Latest filing published 13 Jan 2023 for SynAct Pharma AB.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Patrik Renblad: trading record in brief
Patrik Renblad discloses dealings in SynAct Pharma AB to Finansinspektionen. Over a trading history stretching from 8 April 2022 to 13 January 2023, the count stands at 5 filings.
Every open-market trade on record is a purchase: 1 purchase worth €116, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant.
On 13 January 2023 came the latest disclosure, a share grant in SynAct Pharma AB. The last insider purchase was made public on 8 April 2022, 1,676 days ago. Most trades are made public on the day they happen. The regulation allows three business days to notify a trade (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Patrik Renblad
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 90,000 shares0OptionFI:csv-19d8ca2f9f2fb24cd074
- 9,127 shares@ SEK 63.0095.6% of flowBTA (betald tecknad aktie)ISIN SE0017768963FI:csv-266ec12752b11f336497
- 400 shares@ SEK 63.004.2% of flowBTA (betald tecknad aktie)ISIN SE0017768963FI:csv-1ed3de0af1356abc4a04
- 4,400 shares0Teckningsrätt/UniträttISIN SE0017768955FI:csv-1675e4c9752142986ffc
- 3,400 shares@ SEK 0.350.2% of flowTeckningsrätt/UniträttISIN SE0017768955FI:csv-a82597a4ddb7a0dcc2a0Canonical exit: 7 Jul 2022 (T+90)
5 of 5 declarations